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Abstract
Poly(glycine-alanine) (polyGA) is one of the polydipeptides expressed in Frontotemporal
Dementia and/or Amyotrophic Lateral Sclerosis 1 caused by C9ORF72 mutations and accu-
mulates as inclusion bodies in the brain of patients. Superficially these inclusions are similar
to those formed by polyglutamine (polyQ)-expanded Huntingtin exon 1 (Httex1) in Hunting-
ton’s disease. Both have been reported to form an amyloid-like structure suggesting they
might aggregate via similar mechanisms and therefore recruit the same repertoire of endog-
enous proteins. When co-expressed in the same cell, polyGA101 and Httex1(Q97) inclusions
adopted immiscible phases suggesting different endogenous proteins would be enriched.
Proteomic analyses identified 822 proteins in the inclusions. Only 7 were specific to polyGA
and 4 specific to Httex1(Q97). Quantitation demonstrated distinct enrichment patterns for
the proteins not specific to each inclusion type (up to ~8-fold normalized to total mass). The
proteasome, microtubules, TriC chaperones, and translational machinery were enriched in
polyGA aggregates, whereas Dnaj chaperones, nuclear envelope and RNA splicing proteins
were enriched in Httex1(Q97) aggregates. Both structures revealed a collection of folding
and degradation machinery including proteins in the Httex1(Q97) aggregates that are risk
factors for other neurodegenerative diseases involving protein aggregation when mutated,
which suggests a convergence point in the pathomechanisms of these diseases.
Introduction
The formation of protein inclusions is a hallmark of many neurodegenerative diseases. Inclu-
sions are thought to derive primarily from the clustering of misfolded proteins into a
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centralized deposit [1]. While superficially many inclusions arising from different proteins
appear similar in structure and morphology to each other, the mechanisms that mediate inclu-
sion formation remains incompletely understood and involves multiple components. In the
aggresome model, misfolded proteins are delivered by dynein-mediated transport to a central-
ized deposit near the microtubule organizing center [2]. However, other mechanisms must
exist because other misfolded proteins form immiscible inclusion bodies when produced in
the same cell [3–5]. Other models can explain multiple bodies as Q-bodies, JUNQ and iPOD
structures, which have been suggested to operate as interconnected quality control processing
centers for handling different classes of misfolded proteins (reviewed in [6]). One caveat with
these models is that they explain inclusion assembly as primarily directed by cellular quality
control mechanisms for proteins of different states of (mis) foldedness and less so by the physi-
cochemical properties of the aggregating proteins. This is important in context of the physico-
chemical process of protein phase separation, which has emerged as a major mechanism to
form membrane-less organelle-like condensates [7]. Phase separation into multiple immiscible
phases may underlie, at least in part, the discrete inclusion structures seen by different mis-
folded proteins. Accordingly, different endogenous proteins may be directed to different
aggregate phases based on either shared physicochemical properties or because they are
recruited as part of quality control mechanisms to manage the formation or clearance of differ-
ent aggregate phases.
Here we sought to assess whether two different and unrelated disease-associated mutant
proteins that form superficially similar-appearing inclusions in cell culture, but which are
immiscible in the same cell, share a similar or different pattern of co-recruitment of endoge-
nous proteins. The two proteins include the exon 1 fragment of Huntingtin (Httex1), which
accumulates into intraneuronal inclusions in Huntington Disease [8] and a dipeptide polymer
of glycine-alanine (polyGA) that forms intraneuronal inclusions in Amyotrophic Lateral Scle-
rosis (ALS) and Frontotemporal Dementia (FTD) [9]. Both of these inclusions are SDS-insolu-
ble and amyloid-like [10, 11].
The aggregation of mutant Httex1 is triggered by an abnormally expanded polyglutamine
(polyQ) sequence encoded in exon 1 that arises by CAG trinucleotide repeat expansions [12,
13]. Long polyglutamine sequences form cytoplasmic or nuclear inclusions in animal and
mouse models and are associated with a pathological cascade of events (reviewed in [1]). In
FTD and ALS patients caused by C9ORF72 GGGGCC hexanucleotide repeat expansion muta-
tions, protein inclusions arise from the aggregation of polydipeptide repeats (PDRs) expressed
abnormally from the expanded GGGGCC hexanucleotide repeat sequence. 5 different PDRs
are expressed, namely dipeptide polymers of proline-arginine (polyPR), glycine-arginine
(polyGR), proline-alanine (polyPA), proline-glycine (PolyPG) in addition to polyGA. Of these
polyPR and polyGR are profoundly toxic when expressed in cell culture and animal models,
with the toxicity targeting mechanisms in ribosome biogenesis, translation, and actin cytoskel-
eton among others [14–21]. PolyGA appears less toxic than the other PDRs although it has
been reported to confer toxicity in some models [22–30]. PolyGA inclusions are however
more widespread in FTD-ALS patient brain tissue compared to the other PDRs [9].
Methods
Plasmids
A pEGFP-based construct expressing polyGA dipeptide repeat length of 101 dipeptides
(polyGA101) was generated as described previously [21]. This construct expresses a GFP fusion
tag at N-terminus of the polyGA. pT-REx vector expressing exon 1 of Htt (Httex1) with polyQ
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sequence length of 97 and C-terminal mCherry or GFP fluorescent tags were prepared as pre-
viously described [31, 32].
Cell lines
Neuro-2a cells, obtained originally from the American Type Culture Collection (ATCC), were
maintained in Opti-MEM (Life Technologies). The medium was supplemented with 10% v/v
fetal calf serum, 1 mM glutamine, and 100 Unit mL–1 penicillin and 100 μg mL–1 streptomycin,
and cells were kept in a humidified incubator with 5% v/v atmospheric CO2 at 37˚C.
Transfections
Neuro2a cells were transiently transfected with the vectors using Lipofectamine 2000 reagent
(Life Technologies). Specific transfection conditions for the different culture vessel types at
densities of 9 × 104 (Ibidi 8-well μ-chamber) or 6 × 106 (T75 flasks). The following day cells
(confluency of 80–90%) were transiently transfected with 1.25 or 60 μL Lipofectamine 2000
and 0.5 or 24 μg vector DNA, respectively, as per the manufacturer’s instructions (Life Tech-
nologies). The next day, the medium was changed to Opti-MEM, and for the time course the
medium was refreshed daily.
Confocal imaging
Cells co-transfected with EGFPC2-GA101 and Httex1Q97-mCherry were fixed 24 h after transfec-
tion in 4% w/v paraformaldehyde for 15 min at room temperature. Nuclei were counterstained
with Hoechst 33342 at 1:200 dilution (Thermo Fisher Scientific, San Jose, CA) for 30 min then
washed twice in phosphate buffered saline (PBS). Fixed cells were imaged on a Leica SP5 confo-
cal microscope using HCX PL APO CS 40× or 63× oil-immersion objective lens (NA 1.4) at
room temperature. Laser used: 405 nm excitation, 445–500 nm emission–Hoechst 33342; 488
nm excitation, 520–570 nm emission–GFP; 561 nm excitation, 590 nm emission–mCherry. Sin-
gle colour controls were used to establish and remove bleed through of the emission filter band-
widths. FIJI version of ImageJ [33] and Inkscape software were used for image processing.
Purification of PolyGA and polyQ aggregates
Neuro-2a cells expressing either GFP-tagged GA101 or Httex1Q97 in 3 replicates were har-
vested by pelleting (200 g; 5 min; 24˚C) 24 h post transfection. Cell pellets were resuspended in
lysis buffer (20 mM Tris, pH 8.0; 2 mM MgCl2; 150 mM NaCl; 1% (w/v) Triton X-100; 20
Units/mL Benzonase, Novagen; 1× complete mini-protease cocktail; Roche) and then incu-
bated for 30 min on ice. Lysates were diluted 2 times with PBS supplemented with protease
inhibitor and aggregates were pelleted at 1000 g for 6 minutes. The aggregates were washed
twice with 1 mL PBS, then resuspended in 1 ml PBS and subjected to fluorescence-activated
cell sorting (FACS) on a BD FACS Aria III instrument with an outlet nozzle of 100 μm in
diameter. The flow rate was adjusted to *500 events/min, and EGFP fluorescence was moni-
tored for sorting. Sorted aggregates were pelleted (12,000 g; 5 min; 4˚C), resuspended in PBS
and washed 3 times by pelleting as above and resuspension in PBS. The final pellets were har-
vested by pelleting (21,000 g, 6 min, 4˚C) and dissolved in 10 μL neat formic acid for 30 min at
37˚C, vortexed for 20 seconds and sonicated for 1 min three times then incubated in a shaking
microfuge tube incubator (30 min, 37˚C). Samples were neutralized to pH 7.0 by titration with
unbuffered 3 M Tris. The protein concentration in the sample was determined by a Bradford
assay using bovine serum albumin as mass standard. A total protein of 200 μg was further pro-
cessed for mass spectrometry analysis.
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Collection of cells by pulse shape analysis
To assess the impact of polyGA aggregation on whole proteome, Neuro2a cells expressing
GFP-tagged polyGA in 3 replicates were harvested 48 h post transfection by resuspension in
PBS with a cell scraper. Cells were pelleted (120 g; 6 min) and resuspended in 2 mL PBS sup-
plemented with 10 units/mL DNase I and filtered through 100 μm nylon mesh before analysis
by flow cytometry. DAPI or Sytox (Thermo Fisher Scientific) was spiked into cell suspensions
just before sorting to stain dead cells. Cells were analyzed by a FACS ARIA III cell sorter (BD
Biosciences) equipped with 405-nm, 488-nm, 561-nm and 640-nm lasers. Live cells were gated
using side and forward scatter as described previously [34]. Cells were further gated into cells
with polyGA101 in the soluble form (ni) and those with polyGA101 inclusions (i) by pulse shape
analysis (PulSA) as previously described [34]. Each gate recovered between 0.8–1 × 106 cells
which were sorted directly into PBS and then snap frozen in liquid nitrogen and stored at–
80˚C until used.
Sample preparation for whole proteome analysis
Sorted cell populations were thawed and resuspended in 100 μl RIPA lysis buffer (25 mM Tris-
HCl, pH 7.4, 150 mM NaCl, 1% v/v NP-40, 0.1% w/v SDS, 1% w/v sodium deoxycholate, 1×
complete mini-protease mixture; Roche), and incubated on ice for 30 min. The concentration
of proteins was measured by the Pierce microBCA Protein Assay according to the manufac-
turer’s instruction (Thermo Fisher Scientific). Equal amounts of protein for each sample were
precipitated with six volumes of pre-chilled (−20˚C) acetone, and incubation overnight at
−20˚C. Samples were then pelleted (21,000 g, 10 min, 4˚C). Acetone was decanted without dis-
turbing the protein pellet. The pellets were washed once with pre-chilled acetone then allowed
to dry for 10 min. The protein precipitates were resuspended in 100 μl 0.1 M triethylammo-
nium bicarbonate (TEAB) and were vortexed and then sonicated 3 times for 30 s. The samples
were further processed for mass spectrometry analysis.
Protein sample preparation for mass spectrometry
Proteins were subjected to reduction with 10 mM tris(2-carboxyethyl)phosphine (TCEP), pH
8.0, and alkylation with 55 mM iodoacetamide for 45 min, followed by trypsin digestion
(0.25 μg, 37˚C, overnight). The resultant peptides were adjusted to contain 1% v/v formic acid
then desalted by solid-phase extraction with an SPE cartridge (Oasis HLB 1 cc Vac Cartridge,
Waters Corp., Milford, MA) pre-washed with 1 ml of 80% v/v acetonitrile (ACN) containing
0.1% v/v trifluoroacetic acid (TFA) and equilibrated with 1.2 ml of 0.1% v/v TFA three times.
Samples were then loaded on the cartridge and washed with 1.5 ml of 0.1% v/v TFA before
being eluted with 0.8 ml of 80% v/v ACN containing 0.1% v/v TFA and collected in 1.5 ml
microcentrifuge tubes. Peptides were then lyophilized by freeze drying (Virtis, SP Scientific,
Warminster, PA). The peptides were resuspended in 100 μl distilled water and quantified
using microBCA assay with bovine serum albumin as the mass standard. Then, 10 μg of each
sample (in a volume of 50 μl containing 100 mM TEAB) were differentially labelled by reduc-
tive dimethyl labelling using equal volumes (2 μl) of 4% light formaldehyde (CH2O) or 4%
medium formaldehyde (CD2O, 98% D) and 0.6 M Sodium cyanoborohydride (NaCNBH3).
The peptide solutions were incubated on an Eppendorf Thermomixer (Eppendorf South
Pacific Pty. Ltd., Macquarie Park, NSW, Australia) at room temperature for 1 h. After quench-
ing with 8 μl of 1% v/v ammonium hydroxide followed by further quenching with 8 μl of neat
formic acid, dimethyl-labelled peptides were combined in equal amounts prior to liquid chro-
matography-nano electrospray ionization-tandem mass spectrometry (LC-nESI-MS/MS)
analysis.
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NanoESI-LC-MS/MS analysis
Peptides were analyzed by LC-nESI-MS/MS using an Orbitrap Lumos mass spectrometer
(Thermo Fisher Scientific) fitted with nanoflow reversed-phase-HPLC (Ultimate 3000 RSLC,
Dionex, Thermo Fisher Scientific). The nano-LC system was equipped with an Acclaim Pep-
map nano-trap column (Dionex—C18, 100 Å, 75 μm × 2 cm) and an Acclaim Pepmap RSLC
analytical column (Dionex—C18, 100 Å, 75 μm × 50 cm, Thermo Fisher Scientific). For each
LC-MS/MS experiment, 1 μg (whole proteome) or 0.135 μg (aggregate proteome) of the pep-
tide mix was loaded onto the enrichment (trap) column at a flow of 5 μl/min in 3% CH3CN
containing 0.1% v/v formic acid for 6 min before the enrichment column was switched in-line
with the analytical column. The eluents used for the LC were 5% DMSO/0.1% v/v formic acid
(solvent A) and 100% CH3CN/5% DMSO/0.1% formic acid v/v (solvent B). The gradient used
was 3% v/v B to 20% B for 95 min, 20% B to 40% B in 10 min, 40% B to 80% B in 5 min and
maintained at 80% B for the final 5 min before equilibration for 10 min at 3% B prior to the
next analysis.
The mass spectrometer was operated in positive-ionization mode with spray voltage set at
1.9 kV and source temperature at 275˚C. Lockmass of 401.92272 from DMSO was used. The
mass spectrometer was operated in the data-dependent acquisition mode, with MS spectra
acquired by scanning from m/z 400–1500 at 120,000 resolution with an AGC target of 5e5. For
MS/MS, the “top speed” acquisition method mode (3 s cycle time) on the most intense precur-
sor was used whereby peptide ions with charge states�2 were isolated with an isolation win-
dow of 1.6 m/z and fragmented with high energy collision (HCD) mode, with a stepped
collision energy of 30 ± 5%. Product ion spectra were acquired in the Orbitrap at 15,000 reso-
lution. Dynamic exclusion was activated for 30s.
Proteomic data analysis
Raw data were analyzed using Proteome Discoverer (version 2.3; Thermo Scientific) with the
Mascot search engine (Matrix Science version 2.4.1). Database searches were conducted
against the Swissprot Mus musculus database (version 2016_07; 16794 proteins) combined
with common contaminant proteins. GFP sequence (UniProt ID: P42212) was also
concatenated to the Httex1Q97 and PolyGA101 sequences. Search was conducted with 20 ppm
MS tolerance and 0.2 Da MS/MS tolerance. The enzyme specificity was set as trypsin. The
maximum number of missed cleavage sites permitted was two, and the minimum peptide
length required was six. Variable modifications were used for all experiments: oxidation (M),
acetylation (Protein N-term), dimethylation (K), dimethylation (N-Term), 2H (4) dimethyla-
tion: (K) and 2H (4) dimethylation (N-term). A fixed modification used for all experiments
was carbamidomethyl (C). The false discovery rate (FDR) was calculated by the Percolator
node in Proteome Discoverer v 2.3.0.81 and was set to 0.5% at the peptide identification level
and 1% at the protein identification level. Proteins were filtered for those containing at least
one unique peptide in all n = 3 biological replicates. Peptide quantitation was performed in
Proteome Discoverer v.2.3 using the precursor ion quantifier node. Dimethyl labelled peptide
pairs were established with a 2 ppm mass precision and a signal to noise threshold of 3. The
retention time tolerance of isotope pattern multiplex was set to 0.6 min. Two single peak or
missing channels were allowed for peptide identification. The protein abundance in each repli-
cate was calculated by summation of the unique peptide abundances that were used for quanti-
tation (light or medium derivatives). The peptide group abundance and protein abundance
values were normalized to account for sample loading. In brief, the total peptide abundances
for each sample was calculated and the maximum sum for all files was determined. The nor-
malization factor was the factor of the sum of the sample and the maximum sum in all files.
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After calculating the normalization factors, the Peptide and Protein Quantifier node normal-
ized peptide group abundances and protein abundances by dividing abundances with the nor-
malization factor over all samples. The normalized protein abundances were imported into
Perseus software (v 1.6.5.0). Protein abundances were transformed to log2 scale. The samples
were then grouped according to the replicates and protein intensities in these replicates were
filtered, so at least two data points were present in total. For aggregate proteomes, proteins list
was manually inspected to determine proteins that are completely specific to only one type of
aggregate before missing quantitation values were filled with a constant (zero filling). For pair-
wise comparison of proteomes and determination of significant differences in protein abun-
dances, paired Student’s t test based on permutation-based FDR statistics was then applied
(250 permutations; FDR = 0.05; S0 = 0.1). This was justified on the basis the proteomics abun-
dance data was normally distributed.
Bioinformatics
Protein interaction networks were generated using Cytoscape 3.7.1 [35] built-in STRING
(v11.0) [36] using active interaction sources parameters on for Experiments, Databases, Co-
expression neighborhood, Gene Fusion and Cooccurrence unless otherwise indicated. The
minimum required interaction score setting was 0.9 (highest confidence) unless otherwise
indicated. The corresponding enriched GO annotation terms were determined by calculating
their enrichment P-value, which we compute using a Hypergeometric test, as explained in
[37]. The P-values are corrected for multiple testing using the method of Benjamini and Hoch-
berg [38]. Selected GO terms were used to manually re-arrange nodes and were added to pro-
tein interaction network using Inkscape.
IUPred [39] were applied to predict the intrinsically unstructured/disordered regions of
proteins significantly enriched in polyGA101 or Httex1Q97 aggregates. Glutamine content was
analyzed with the web-server COPid [40] (http://crdd.osdd.net/raghava/copid/whole_comp.
html). A control set of 100 random proteins (S1 Table) was generated from a list of the mouse
proteome obtained from the Uni-ProtKB database (http://www.uniprot.org/uniprot/?query=
reviewed:yes+AND+organism:10090&random=yes). The Mann-Whitney- Wilcoxon test was
employed to determine significant differences.
Statistical analysis
The details of the tests were reported in the figure legends. All statistical analyses were per-
formed with GraphPad Prism v 7.05 (Graphpad Software Inc., San Diego, CA). Significant
results were defined on the figures for P< 0.05.
Data availability
The MS proteomic data have been deposited to the ProteomeXchange Consortium via the
PRIDE [41] partner repository with the dataset identifiers PXD018505 for aggregate proteome
data and PXD018824 for whole proteome data.
Results & discussion
We previously reported polyGA101 to be mildly toxic to cultured Neuro2a cells and to induce a
distinct network of proteome changes that occur compared to the arg-rich PDRs [21]. We also
noted a distinction to the other PDRs in forming large inclusions that are morphologically
similar to the inclusions formed by polyQ. When we co-expressed Httex1Q97 as a fusion to
mCherry, we found the polyGA101 and Httex1Q97 formed discrete inclusions in the same cell
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with no apparent colocalization (Fig 1A–1B). This suggested that any concomitant co-aggrega-
tion patterns that arise with endogenous proteins may involve highly distinct proteins even
though both proteins seem to form amyloid-like fibrils.
To investigate these potential differences, pellets recovered from lysates of neuro2a cells
expressing GFP-tagged Httex1Q97 or GFP-tagged polyGA101 were sorted to purify the aggre-
gates using flow cytometry via monitoring the GFP fluorescence. Quantitative proteomics, by
way of dimethyl isotope labelling, was used to define the proteins enriched in each aggregate
class (Httex1Q97 versus polyGA101) after normalization to total mass of protein. We observed
822 proteins in both inclusions (S2 Table). Of these 70 were significantly enriched in polyGA
inclusions (3 replicates, a permutation-based FDR cut-off of 5% and S0 of 0.1) and 51 were
enriched in Httex1Q97 (Tables 1 and S2 and Fig 2A). 7 proteins were identified exclusively in
polyGA inclusions (Phlda1, Etfa, Cbx4, Soga3, Vasp, Cops7a and Dtx3l) and 4 proteins identi-
fied exclusively in Httex1Q97 inclusions (Pcnt, Lsm12, Specc1l and Arfgap2). We also noted
the GFP moiety (which was identified from both Httex1 and polyGA fusions) was enriched in
the polyGA aggregates suggesting that the inclusions formed by polyGA contain less mass of
associated proteins than those formed by Httex1. This could arise by more non-specific inter-
actions to the Httex1 inclusions or by polyGA forming a greater proportion (by mass) of the
inclusion composition than for Httex1 inclusions.
Of the proteins found uniquely in polyGA or polyQ inclusions, several of the proteins
appeared unconnected to other proteins in the protein-protein interaction analysis (Fig 2B).
Fig 1. Httex1Q97 and polyGA101 form distinct inclusions in neuro2a cells. Confocal micrographs of neuro2a cells
co-expressing GFP-tagged GA101 (yellow) and mCherry-tagged Httex1Q97 (magenta), fixed 24 hr post-transfection and
stained with Hoechst33258 (cyan) to visualize nuclei. The dotted white lines show the outlines of cells (manually
traced). Scale bar represents 5 μm. Panels A and B show two different scales of view.
https://doi.org/10.1371/journal.pone.0233247.g001
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Table 1. Proteins enriched in inclusions of polyGA101 and Httex1Q97�.
Enriched in polyGA101 Enriched in Httex1Q97
Description Gene
ID
log2 enrichment
(mean ± SD)
Description Gene ID log2 enrichment
(mean ± SD)
Proteins uniquely identified in either of the aggregate type
Pleckstrin homology-like domain family A member
1
Phlda1 8.91±0.11 Pericentrin Pcnt 5.33±0.84
Electron transfer flavoprotein subunit alpha,
mitochondrial
Etfa 7.24±0.70 Protein LSM12 homolog Lsm12 5.90±0.24
E3 SUMO-protein ligase CBX4 Cbx4 7.21±1.16 Cytospin-A Specc1l 7.04±0.42
Protein SOGA3 Soga3 6.96±0.10 ADP-ribosylation factor GTPase-activating
protein 2
Arfgap2 8.33±0.29
Vasodilator-stimulated phosphoprotein Vasp 6.88±1.15
COP9 signalosome complex subunit 7a Cops7a 6.83±0.42
E3 ubiquitin-protein ligase DTX3L Dtx3l 5.87±1.67
Proteins relatively enriched in either of the aggregate type
Pleckstrin homology domain-containing family A
member 2
Plekha2 6.57±2.79 Ubiquilin-1 Ubqln1 8.27±2.65
Tryptophan—tRNA ligase, cytoplasmic Wars 4.44±2.09 Myosin phosphatase Rho-interacting protein Mprip 5.65±1.96
DNA replication licensing factor MCM3 Mcm3 3.73±1.22 SAP domain-containing ribonucleoprotein Sarnp 5.56±1.78
Eukaryotic translation initiation factor 2 subunit 1 Eif2s1 3.65±0.71 Hsc70-interacting protein St13 4.78±0.36
E3 ubiquitin-protein ligase RNF126 Rnf126 2.98±1.30 Histone H3.1 Hist1h3a 4.30±1.28
UBX domain-containing protein 1 Ubxn1 2.66±1.21 Clathrin interactor 1 Clint1 4.28±0.91
Proteasome subunit beta type-4 Psmb4 2.60±0.63 Coiled-coil-helix-coiled-coil-helix domain-
containing protein 2
Chchd2 4.02±0.73
Sequestosome-1 Sqstm1 2.47±0.03 RNA-binding protein FUS Fus 3.26±1.23
Interferon-inducible double-stranded RNA-
dependent protein kinase activator A
Prkra 2.40±0.75 Tight junction protein ZO-1 Tjp1 3.25±0.93
Sorting nexin-3 Snx3 2.36±0.29 Ubiquitin-associated protein 2 Ubap2 3.24±0.36
Nuclear migration protein nudC Nudc 2.17±0.57 Small glutamine-rich tetratricopeptide
repeat-containing protein alpha
Sgta 3.22±0.80
Receptor of activated protein C kinase 1 Rack1 2.17±0.28 DnaJ homolog subfamily B member 1 Dnajb1 3.11±1.11
40S ribosomal protein S2 Rps2 2.12±0.54 Chromobox protein homolog 1 Cbx1 3.10±0.36
Nuclear fragile X mental retardation-interacting
protein 2
Nufip2 2.11±0.51 Ubiquilin-2 Ubqln2 3.06±0.77
26S proteasome non-ATPase regulatory subunit 12 Psmd12 2.09±0.67 Phosphatidylinositol-binding clathrin
assembly protein
Picalm 2.81±0.25
Vigilin Hdlbp 2.07±0.12 CUGBP Elav-like family member 1 Celf1 2.51±0.37
Insulin-like growth factor 2 mRNA-binding protein
3
Igf2bp3 2.06±0.78 Transgelin-2 Tagln2 2.17±0.49
GTP cyclohydrolase 1 Gch1 2.04±0.64 RNA-binding protein 25 Rbm25 2.16±0.51
Fructose-bisphosphate aldolase A Aldoa 2.00±0.82 Nucleolysin TIAR Tial1 2.06±0.19
60S ribosomal protein L10 Rpl10 1.99±0.40 Caprin-1 Caprin1 2.04±0.43
ATPase WRNIP1 Wrnip1 1.98±0.73 Probable ATP-dependent RNA helicase
DDX17
Ddx17 2.02±0.18
Ubiquitin fusion degradation protein 1 homolog Ufd1l 1.95±0.63 Protein PRRC2C Prrc2c 2.01±0.48
Proteasome subunit alpha type-6 Psma6 1.93±0.64 Ankyrin repeat domain-containing protein
17
Ankrd17 1.95±0.26
40S ribosomal protein S27 Rps27 1.91±0.34 Pre-mRNA-processing factor 40 homolog A Prpf40a 1.82±0.23
26S proteasome non-ATPase regulatory subunit 3 Psmd3 1.91±0.71 DnaJ homolog subfamily C member 9 Dnajc9 1.78±0.32
Proteasome subunit beta type-7 Psmb7 1.91±0.80 Protein DEK Dek 1.78±0.76
Adenine phosphoribosyltransferase Aprt 1.84±0.63 Hepatocyte growth factor-regulated tyrosine
kinase substrate
Hgs 1.73±0.25
(Continued)
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Table 1. (Continued)
Enriched in polyGA101 Enriched in Httex1Q97
Description Gene
ID
log2 enrichment
(mean ± SD)
Description Gene ID log2 enrichment
(mean ± SD)
Cytochrome c oxidase subunit NDUFA4 Ndufa4 1.82±0.28 Ubiquitin-associated protein 2-like Ubap2l 1.65±0.20
Interferon-induced protein with tetratricopeptide
repeats 1
Ifit1 1.76±0.50 Nuclear pore complex protein Nup214 Nup214 1.65±0.17
Proteasome subunit beta type-5 Psmb5 1.74±0.37 Poly [ADP-ribose] polymerase 1 Parp1 1.60±0.47
60S ribosomal protein L23 Rpl23 1.73±0.20 Calponin-3 Cnn3 1.60±0.32
T-complex protein 1 subunit eta Cct7 1.72±0.38 DnaJ homolog subfamily A member 2 Dnaja2 1.58±0.63
E3 ubiquitin-protein ligase TRIM32 Trim32 1.72±0.40 Serine/arginine repetitive matrix protein 2 Srrm2 1.55±0.60
ZW10 interactor Zwint 1.68±0.31 Muscleblind-like protein 2 Mbnl2 1.54±0.34
Cyclin-dependent kinase 1 Cdk1 1.59±0.30 Protein phosphatase 1 regulatory subunit
12A
Ppp1r12a 1.50±0.44
ATP-dependent 6-phosphofructokinase, platelet
type
Pfkp 1.57±0.33 Poly(rC)-binding protein 1 Pcbp1 1.41±0.33
Nuclear protein localization protein 4 homolog Nploc4 1.54±0.61 TAR DNA-binding protein 43 Tardbp 1.41±0.15
Large proline-rich protein BAG6 Bag6 1.48±0.33 Hexokinase-1 Hk1 1.41±0.57
26S proteasome non-ATPase regulatory subunit 14 Psmd14 1.48±0.30 Poly(rC)-binding protein 3 Pcbp3 1.35±0.16
Malate dehydrogenase, cytoplasmic Mdh1 1.48±0.22 5’-3’ exoribonuclease 2 Xrn2 1.32±0.36
ADP-sugar pyrophosphatase Nudt5 1.47±0.11 Heterogeneous nuclear ribonucleoprotein F Hnrnpf 1.29±0.43
26S protease regulatory subunit 6A Psmc3 1.42±0.44 Pumilio homolog 1 Pum1 1.22±0.07
Bifunctional glutamate/proline—tRNA ligase Eprs 1.39±0.42 Lamina-associated polypeptide 2, isoforms
alpha/zeta
Tmpo 1.22±0.46
Aminoacyl tRNA synthase complex-interacting
multifunctional protein 1
Aimp1 1.30±0.49 Tropomodulin-3 Tmod3 1.21±0.37
Ribosome-binding protein 1 Rrbp1 1.26±0.39 14-3-3 protein beta/alpha Ywhab 1.15±0.43
40S ribosomal protein S27-like Rps27l 1.23±0.42 Plectin Plec 0.97±0.20
Ras GTPase-activating protein-binding protein 1 G3bp1 1.18±0.39 Small ubiquitin-related modifier 1 Sumo1 0.83±0.22
Glyceraldehyde-3-phosphate dehydrogenase Gapdh 1.15±0.29 Regulator of nonsense transcripts 1 Upf1 0.82±0.21
Dihydropyrimidinase-related protein 2 Dpysl2 1.09±0.32 Vimentin Vim 0.72±0.13
Dihydropyrimidinase-related protein 3 Dpysl3 1.05±0.05 Nuclear pore complex protein
Nup98-Nup96
Nup98 0.68±0.15
Ataxin-10 Atxn10 1.05±0.20 Importin subunit alpha-1 Kpna2 0.58±0.10
ATP-binding cassette sub-family E member 1 Abce1 1.04±0.25
60S ribosomal protein L38 Rpl38 1.03±0.29
Multifunctional protein ADE2 Paics 0.98±0.25
Polymerase delta-interacting protein 3 Poldip3 0.97±0.11
Melanoma-associated antigen D1 Maged1 0.94±0.23
Dihydropyrimidinase-related protein 1 Crmp1 0.92±0.15
60S acidic ribosomal protein P0 Rplp0 0.89±0.28
ADP/ATP translocase 2 Slc25a5 0.89±0.13
T-complex protein 1 subunit beta Cct2 0.88±0.18
Eukaryotic translation initiation factor 3 subunit D Eif3d 0.87±0.26
T-complex protein 1 subunit delta Cct4 0.84±0.22
Tubulin beta-5 chain Tubb5 0.79±0.12
26S protease regulatory subunit 10B Psmc6 0.76±0.13
Golgi-associated plant pathogenesis-related protein
1
Glipr2 0.75±0.19
IgE-binding protein Iap 0.75±0.19
Cell division control protein 42 homolog Cdc42 0.71±0.13
(Continued)
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This result might be anticipated if these proteins partition into the aggregates based on their
physicochemical properties rather than through a biological mechanism targeting inclusion
assembly or clearance. Two of the proteins found exclusively in the polyGA aggregates (Phlda1
and Etfa) have been previously shown to have altered expression patterns in ALS models
which may indicate a biological consequence of their coaggregation into the inclusions.
Phlda1 was previously shown as upregulated in Fus-mutant motor neurons and suggested to
operate as adaptive response to protect against apoptosis [42]. Phlda1 was also observed upre-
gulated in sporadic ALS fibroblasts treated to stress compared to controls [43]. Etfa is a mito-
chondrial protein that was upregulated pre-symptomatically in a mouse transgenic SOD1
model of ALS [44] and downregulated after symptom development [45]. Hence the changed
expression of Phlda1 and Etfa may arise from depleted activity arising from their sequestration
into inclusions.
More notable connections to ALS biology were observed in the ensemble of proteins found
in both the polyGA and Httex1 inclusions. Namely in C9ORF72 mediated FTD-ALS brain tis-
sue, a subset of inclusions is non-reactive to TDP-43 [46]. In most of the other forms of
FTD-ALS that are not caused by C9ORF72 mutation, TDP-43-reactive inclusions are a key
pathological signature of neurons in disease [47]. TDP-43 negative inclusions were previously
found to be immunoreactive for polyGA, suggesting they form by polyGA aggregation [48,
49]. We observed TDP43 preferentially enriched in the Httex1Q97 inclusions raising the possi-
bility that while TDP43 co-recruits to inclusions, it prefers associating with inclusions formed
by proteins other than polyGA (Table 1). In addition, the TDP43-negative inclusions seen in
vivo are immunoreactive to p62 [50] and lack immunoreactivity to FUS, optineurin, alpha-
internexin and neurofilament [51, 52]. In our data p62 (also called sequestesome 1) is one of
the most enriched proteins in polyGA inclusions, which is consistent with previous findings
showing p62 binding to polyGA [10]. On the other hand Fus appeared diminished from
polyGA inclusions by virtue of its enrichment in Httex1Q97 inclusions, which has been
observed previously in cell models of polyQ aggregation and human pathology [31, 53–55].
Hence these data point to the cell model of polyGA inclusions mimicking the process of aggre-
gation and recruitment seen in vivo and also providing specificity of co-recruitment relative to
Httex1Q97.
Analysis of the differences is shown visually in Fig 2B by a (STRING) protein-protein inter-
action map and annotation to selected functional networks that cluster well with the STRING
networks. Analysis of the genes enriched to either inclusion type yielded an enrichment for
gene ontology and KEGG networks of microtubule cytoskeleton, proteasome complex, chap-
erones, RNA splicing and nuclear envelope (Fig 2B and S3 Table). The most significantly
ranked GO terms show a notable cluster of protein quality control-related terms (Fig 2C and
Table 1. (Continued)
Enriched in polyGA101 Enriched in Httex1Q97
Description Gene
ID
log2 enrichment
(mean ± SD)
Description Gene ID log2 enrichment
(mean ± SD)
Non-POU domain-containing octamer-binding
protein
Nono 0.67±0.09
Aspartate aminotransferase, cytoplasmic Got1 0.45±0.05
� Only proteins that meet significance cut-off (hyperbolic curves, permutation-based FDR�0.05, S0 = 0.1). Full table of proteins are shown in S2 Table; Bold are genes
with known causes or risk factors for FTD-ALS (or other neurodegenerative diseases in the case of Picalm); Italics are cellular proteins previously seen to become more
insoluble when Httex1Q97 formed inclusions [73].
https://doi.org/10.1371/journal.pone.0233247.t001
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Fig 2. Proteome recruitment patterns to polyGA101 and Httex1Q97 inclusions. A. Volcano plot of proteins identified in the inclusions. P-values were
calculated by a two-sided one samples t-test with null hypothesis that abundances were unchanged and the log2 ratio was equal to 0. Proteins meeting
stringency thresholds (hyperbolic curves, FDR�0.05, S0 = 0.1) are shown as colored empty circles and proteins unique to each aggregate type are shown as
filled colored circles. B. STRING interaction maps (v.11) determined in Cytoscape (v3.7) for proteins significantly enriched in the inclusions (the full list of
proteins is in S2 Table). The analysis was done at the highest confidence setting (0.9). Each protein was represented by a colored circle sized proportionally to–
log10 (P-value). The color scale represents logarithm of fold change. Selected significantly enriched GO terms (GOCC, GOPB, and UniProt keywords) are
displayed (Full terms are shown in S3 Table). Note the proteins shown without connections at the bottom are those that are seen in the dataset but which do
not have known protein interactions with the other proteins shown. C. The 10 most significantly enriched GO terms (from S3 Table) with proteins identified in
the GO terms colour coded to enrichment (as per panel 2B). D. Analysis of enriched proteomes for low-complexity regions (IUPred-L) and high glutamine
content. Significance of difference was assessed against a control dataset of random mouse proteins (S1 Table) with the Mann-Whitney-Wilcoxon test.
Whiskers extend from 10 to 90%.
https://doi.org/10.1371/journal.pone.0233247.g002
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S3 Table). PolyGA was enriched with proteasome, ribosome and translation machinery sug-
gesting that it might co-aggregate with newly synthesized proteins. Of 11 key GO terms shown
in Fig 2C, 7 contained mixed enrichment patterns for proteins in Httex1 and polyGA inclu-
sions suggesting that both aggregation types converge on mechanisms related to protein fold-
ing, quality control and degradation (GO terms of proteasome, cytoplasmic stress granule,
ubiquitin-dependent protein catabolic process, unfolded protein binding, ERAD pathway, P-
body, and ubiquitin-dependent ERAD pathway). These findings are in accordance with prior
findings that protein aggregation impacts these biological processes and in particular an
involvement in machinery for their clearance and degradation [56–59].
In addition, the data points more directly to proteins and genes implicated in FTD-ALS
phenotype and mechanisms. Nudt5 was also found mildly enriched in polyGA inclusions
(Table 1) and expression of this gene was significantly increased in motor neurons derived
from induced pluripotent stem cells from ALS patients over controls [60]. Another protein of
note mildly enriched in the polyGA aggregates was Dpysl3. A missense mutation that has been
linked to ALS risk in the French population leads to shortened neuronal survival when
expressed in cultured neurons in vitro [61]. Hence it remains plausible that co-aggregation of
these proteins into polyGA inclusions sequesters their activity and renders cells less resilient to
stress triggers.
The Httex1Q97-enriched proteome also yielded noteworthy findings. Previously it was
found that polyQ can preferentially co-recruit proteins containing intrinsically disordered
domains (IDRs) and proteins enriched in glutamine [31, 54]. These patterns were also
observed in our data (Fig 2D). However, polyGA did not show these enrichment patterns,
indicative of specificity for polyQ in recruiting IDRs and Q-rich proteins. These data are con-
sistent with polyQ more selectively co-aggregating other proteins enriched with glutamine.
One such candidate is CREB Binding Protein, which is dysfunctional in Huntington’s Disease.
CREB Binding protein contains a glutamine repeat and is co-aggregated into inclusions
formed by mutant Htt [62–66]. Hence the co-aggregation of CREB binding protein may result
in its loss of activity as one contribution to pathogenesis.
To assess whether the changes in polyGA inclusion formation had other effects on prote-
ome abundance, we expressed polyGA101 and at 48 h after transfection sorted live cells into
those with visible aggregates from those without by a flow cytometry sorting method called
pulse shape analysis [67] (Fig 3A). Pulse shape analysis uses the fluorescence signal width and
height parameters to infer whether the protein has a diffuse localization (ni) or condensed
localization when inclusions form (i). GFP alone does not aggregate and established the refer-
ence (ni) gate for when inclusions form (Fig 3A). PolyGA-GFP fusions formed both i and ni
populations, which we attribute as cells with inclusions and those without respectively (Fig
3A). Assessment of cells with the dye Sytox, which selectively labels the nuclei of dead and
dying cells, revealed cells with inclusions (the i gate) were more reactive to Sytox than cells
with soluble polyGA (ni gate) (Fig 3A inset). We hence excluded cells that were dying from
analysis. As a result, 35% of the remaining live cells expressing polyGA had inclusions (Fig
3A). We sorted these live cells into those with polyGA inclusions versus cells with soluble
polyGA at matched median expression levels (red population in right panel of Fig 3A) for
proteomic analysis. Fig 3B shows the proteomic abundances for cells matched for total har-
vested protein levels (i.e. polyGA inclusions versus soluble polyGA). Out of 2420 proteins
identified, we observed 56 proteins that significantly changed abundance in these sorted cell
populations (Fig 3B and S4 Table). There was an enrichment of GFP peptides (derived from
the GFP-polyGA101 fusion) in the cells with inclusions, which could arise if the inclusions lead
to the GFP becoming quenched. Hence, we caution that the difference in GFP abundance may
contribute to some of the conclusions that can be drawn from this data. However, there was
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Fig 3. Cellular protein abundance changes arising from polyGA101 aggregation. A. Schematic of flow cytometry method of pulse shape analysis
(PulSA) to sort cells enriched with inclusions (i) from those without inclusions (ni). Cells with inclusions display shorter width (W) fluorescence values
versus cells with soluble protein, and typically higher height values (H) arising from the condensed foci of fluorescence inside the cells. Cells were
sorted to exclude dead cells by DAPI reactivity (which–like Sytox–labels the nuclei of dead and dying cells). Inset shows percentage of transfected cells
(for polyGA101-GFP) reactive to Sytox by time after transfection. n = 4, means ± SD shown. B. Volcano plots of proteins that changed their abundance
upon polyGA aggregation. Shown are cells without polyGA101 aggregates (i population) versus cells with soluble polyGA101 (ni population) collected at
matched median GFP fluorescence. The dotted line indicates significance cut-off (hyperbolic curves, FDR�0.05, S0 = 0.1) and proteins meeting
stringency thresholds are shown as colored circles. C. Protein-protein interaction network (STRING v11) of proteins significantly changed in
abundance upon polyGA aggregation (i.e. polyGA101 aggregates (i population) versus cells with soluble polyGA101 (ni population)). The full list of
proteins are in S4 Table. The analysis was done at the highest confidence setting. Each protein was represented by a colored circle sized proportionally
to -log10 (P-value). The color scale represents logarithm of fold change. Selected significantly enriched GO terms (GOCC, GOPB, and UniProt
keywords) are displayed (S5 Table).
https://doi.org/10.1371/journal.pone.0233247.g003
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no overlap in the proteins seen enriched in polyGA inclusions (data in Fig 2 and S3 Table)
with proteins that changed abundance when polyGA shifted from a soluble to aggregated state
(Fig 3C and S4 Table). This provides firmer confidence that the enrichment seen in the
polyGA aggregates arises from co-aggregation rather than changes in gene expression.
Of the genes that changed expression, protein interaction networks yielded significant
enrichment in networks including nuclear speck (GO: 0016607), ribosome biogenesis (GO:
0042254), chromosome (GO:0005694), mitochondrion (GO:0005739) and Golgi-to-ER-traffic
(MMU-6811442) (S5 Table). Some of these pathways would be anticipated to be correlated to
stress responses incurred by protein aggregation or proteostasis imbalance based on links
between ribosome biogenesis and nucleolar stress response [68], ribosome biogenesis and pro-
teostasis imbalance [69], mitochondria as mediators of apoptosis [70], and role of the Golgi as
a stress sensor in neurodegeneration [71]. However, we did not note any striking changes that
pertained to novel mechanisms other than that from this data.
Lastly, we investigated the overlap of proteins enriched in Httex1Q97 inclusions with pro-
teins identified in Httex1 inclusions from other studies. Mitsui et al [72] identified 8 promi-
nent proteins in purified Httex1Q97 inclusions that eluted by SDS-PAGE (HSP84, HSC70, α-
tubulin, β-tubulin, EF-1α, HDJ-1 and HDJ-2 and actin). We observed all of these in our study
suggesting they are enriched in both polyGA and Httex1 inclusions. HDJ-1 and HDJ-2 are
Hsp40 family protein members and we observed significant enrichment of Hsp40 proteins
dnaja2, dnajb1 and dnajc9 in the Httex1Q97 inclusions (S2 Table). Of the others identified by
Mitsui et al we saw no specific enrichment to polyQ inclusions, which suggests that these pro-
teins are recruited to both inclusion types. This conclusion is supported by the enrichment of
HSP84 (which is Hsp90a) and EF1α (which is Eef1a) immunoreactivity to the surface of the
inclusions [72].
We also examined the overlap with our previously reported changes in solubility of whole
cell proteome before versus after inclusions had formed [73] (Fig 4A). In that dataset (Sui et al
[73]) we observed 25 proteins that significantly decreased in solubility as cells expressing
Httex1Q97 shifted from a dispersed unaggregated state to forming inclusions [73] (S6 Table).
Of these, 9 proteins were found in our list of 55 proteins significantly enriched in Httex1Q97
inclusions (Pcbp1, Dnaja2, Sgta, Picalm, Hgs, Clint1, Ubqln1, Ubqln2 and Dnajb1) (Fig 4A).
When we also considered proteins that were identified in either inclusion (full list of proteins
in S2 Table), which are therefore candidate proteins that are recruited to both inclusion types,
we found a further 7 proteins that overlapped with the previous published data from Sui et al
[73]. Analysis of the protein:protein interaction networks by STRING analysis revealed two
robust networks within these proteins that map onto gene ontology enrichments for mecha-
nisms related to protein quality control including positive regulation of proteolysis
(GO:0045862; FDR of 0.0029), positive regulation of ERAD pathway (GO:1904294; FDR of
8.76E-05), heat shock protein binding (GO:0031072; FDR of 2.43E-06) and protein folding
(GO:0006457; FDR of 0.00034) (Fig 4B and full list of GO terms in S6 Table).
Clint1 and Ubqln2 were previously shown to colocalize to polyQ inclusions, supporting
this conclusion [54, 74]. An interesting note with respect to mechanism is that UBQLN2 tar-
gets ubiquitinated substrates for degradation in ERAD and autophagy [75]. Furthermore
mutations in UBQLN2 cause ALS, which appear to lead to an impairment in the degradation
of ubiquitinated proteins [76]. Further supporting an important role linking protein aggrega-
tion and degradation more broadly to these neurodegenerative diseases is the enrichment of
Picalm in the polyQ inclusions. Picalm is a phosphatidylinositol-binding clathrin assembly
protein and has been shown from GWAS to be a top ten risk for Alzheimer’s disease [77, 78].
It has been reported to modulate intracellular APP processing and plaque pathogenesis [79],
modulate autophagy and alter tau clearance [80].
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Collectively the data here reports proteins that co-aggregate into two very different neuro-
degenerative disease proteinaceous deposits. The findings provide specificity of proteins to the
aggregation type that provide useful perspective to that reported by others. Moreover, the
mechanisms of protein clearance and regulation of protein folding-misfolding appear relevant
to both aggregation types and notably of a number of proteins in the Httex1Q97 aggregates
that when mutated are modifiers of ALS risk [81] (list of ALS genes, and mouse protein coun-
terparts, are shown in S7 Table). Therefore, the findings identify a synergy of biological mecha-
nisms involved in protein folding quality control and degradation that appear central to at
least two different neurodegenerative diseases, and possibly more applicable to the other
neurodegenerative diseases involving inappropriate protein aggregation.
Fig 4. Commonalities of proteins found in Httex1Q97 and polyGA101 inclusions with changes in proteome solubility due to Httex1 aggregation.
A. Venn diagram of proteins previously found by Sui et al [73] to change solubility when Httex1 formed inclusions compared to proteins enriched in
Httex1 inclusions over polyGA inclusions (our data here in S2 Table). Proteins highlighted in bold blue are additional proteins seen in our dataset that
are not enriched to Httex1. B. STRING (v11.0) interaction network of the proteins from panel A. Protein names are colour coded to match panel A.
Shown are interactions at highest (0.9) and medium confidence settings (0.4). Note the proteins shown without connections are those that are seen in
the dataset but which do not have known protein interactions with the other proteins shown. Protein nodes are colour coded to selected significant
Gene ontology terms. Full list of GO terms for Biological Process and Molecular Function are shown in S6 Table.
https://doi.org/10.1371/journal.pone.0233247.g004
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